HIV prevention trials at the Thai Red Cross AIDS Research Centre

Nittaya Phanuphak, MD

Community Satellite, AIDS Vaccine 2011
Moving Forward Together: Research literacy and community engagement in 2011 and beyond
Bangkok, September 12, 2011
Ongoing and planned HIV prevention activities and trials among MSM

• Active VCT:
  – MSM-targeted services for PICT, Mobile Clinic, regular HIV testing

• Testing acceptability and feasibility of proved and potential HIV prevention methods:
  – HN120, Test-and-treat, oral PrEP adherence
Provider-Initiated Testing and Counseling (PITC) for HIV at the TRC-AC

Dr. Praphan Phanuphak
Director of TRC-ARC

Cervical and anal Pap smear

STI diagnosis and treatment

HIV Testing

Health check-up package

nPEP

Nutrition service, special event campaign, outreach activities
MSM-targeted services for PITC at the Thai Red Cross Men’s Health Clinic

- Anal Pap and STI services
  - Among 1,429 MSM clients in 2009
    - 52% known HIV+ve
    - 35% known HIV-ve and 13% unknown HIV status

<table>
<thead>
<tr>
<th>Previous HIV status</th>
<th>STI MSM clients</th>
<th>Anal Pap MSM clients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HIV-ve Unknown</td>
<td>HIV-ve Unknown</td>
</tr>
<tr>
<td>Acceptance of HIV testing</td>
<td>34% 98%</td>
<td>77% 85%</td>
</tr>
<tr>
<td>% tested +ve for HIV</td>
<td>8% 13%</td>
<td>13% 33%</td>
</tr>
</tbody>
</table>
MSM-targeted services for PITC in Mobile Health Clinic

- BIA scale with brief advice on exercise tips
- Rapid HIV testing
- Rapid syphilis testing

- 46 clients in 3 sauna venues
- 72% accepted HIV testing
- HIV prevalence 21%
MSM-targeted services to retain HIV-ve MSM for regular HIV testing

Using MSM-targeted services in BKK, Bali, Jakarta

- Anal Pap smear
- BIA scale and health check-up
- nPEP and STI service
- MSM peer supporter team

To retain 350 MSM in the program

- Regular HIV testing for HIV-ve MSM
- Retention in HIV care for HIV+ve MSM

Funded by the NIH/PEPFAR grant
HN120: Acceptability and feasibility of “standard” and “potential” HIV prevention methods

• 100 HIV-ve Thai MSM at the TRC-AC

• Standard HIV prevention package
  • Anti-HIV testing, risk reduction counseling, free condoms and lubricants, treating symptomatic STI, access to nPEP without charge

• Potential HIV prevention methods
  • Daily and intermittent oral PrEP (PLACEBO), topical PrEP (PLACEBO)
  • Asymptomatic STI screening and treatment
  • Internet-based social networking
ENJOY SAFE LOVE

Get Tested EVERY 3 MONTHS

Adam's Love is a one-stop source for safe sex, HIV/AIDS info and fun for all men who love men.

Men's Health Clinic
The Thai Red Cross AIDS Research Centre
104 Ratchadamri Road, Pathumwan, Bangkok 10330
Tel: +66 2 256-4107-09
Hotline 081-930-9393
info@adamslive.org

Ask Our Experts

For more info visit www.adamslive.org
Like us on www.facebook.com/adamslivehailand
Test-and-Treat: Treatment as prevention

• Early diagnosis and treatment (for those eligible for treatment) will limit the risk of both AIDS- and non-AIDS-related health problems

• HPTN 052: 1,763 serodiscordant heterosexual couples
  – Immediate ART (CD4>350, not yet eligible for treatment) led to 96% reduction in HIV transmission to partners, compared to deferred ART

• ?MSM
  – Multiple partners

• Reducing viral load to undetectable levels—in as many people within a community as possible—will greatly reduce the rate of ongoing transmission of HIV
Recruitment and informed consent process

Sign consent form
HIV testing

HIV+ve MSM

Informed consent process for immediate ART

Accept immediate ART or Eligible for ART

Start ART
Evaluate adherence, retention, safety, CD4, HIV-RNA

Refuse immediate ART and not yet eligible for ART

Follow-up every 6 months
Evaluate retention, CD4, HIV-RNA

HIV-ve MSM

Annual plus self-schedule HIV testing

Assess return rate for HIV testing which may be more or less than self-scheduled

Refuse immediate ART and not yet eligible for ART

Evaluate adherence, retention, safety, CD4, HIV-RNA

Standard VCT and ART
Optimization of oral PrEP adherence among Thai MSM

• iPrEx study: oral daily Truvada among MSM and TG in 6 countries
  – Reduced HIV acquisition risk by 44% (95%CI 15-63)
  – Pill use of >90% showed 73% efficacy (95%CI 41 to 88)
  – Detectable drug level showed 95% efficacy (95%CI 70 to 99)

• Randomized controlled trial to test innovative method(s) to optimize adherence of daily oral PrEP among Thai MSM and TG